An advisory panel to the U.S. Centers for Disease Control and Prevention (CDC) will meet on Wednesday to review data on the use of Pfizer Inc (PFE.N) and partner BioNTech’s (22UAy.DE) COVID-19 vaccine in adolescents aged 12 to 15.
Read More